Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Am J Public Health ; 112(S9): S918-S922, 2022 Nov.
Article in English | MEDLINE | ID: covidwho-2141099

ABSTRACT

At-home COVID-19 testing offers convenience and safety advantages. We evaluated at-home testing in Black and Latino communities through an intervention comparing community-based organization (CBO) and health care organization (HCO) outreach. From May through December 2021, 1100 participants were recruited, 94% through CBOs. The odds of COVID-19 test requests and completions were significantly higher in the HCO arm. The results showed disparities in test requests and completions related to age, race, language, insurance, comorbidities, and pandemic-related challenges. Despite the popularity of at-home testing, barriers exist in underresourced communities. (Am J Public Health. 2022;112(S9):S918-S922. https://doi.org/10.2105/AJPH.2022.306989).


Subject(s)
COVID-19 Testing , COVID-19 , Humans , COVID-19/diagnosis , COVID-19/epidemiology , New Jersey , Hispanic or Latino , Delivery of Health Care
2.
Health Affairs ; 39(12):2105-2112, 2020.
Article in English | ProQuest Central | ID: covidwho-1021682

ABSTRACT

Deciding which climate policies to enact, and where and when to enact them, requires weighing their costs against the expected benefits. A key challenge in climate policy is how to value health impacts, which are likely to be large and varied, considering that they will accrue over long time horizons (centuries), will occur throughout the world, and will be distributed unevenly within countries depending in part on socioeconomic status. These features raise a number of important economic and ethical issues including how to value human life in different countries at different levels of development, how to value future people, and how much priority to give the poor and disadvantaged. In this article we review each of these issues, describe different approaches for addressing them in quantitative climate policy analysis, and show how their treatment can dramatically change what should be done about climate change. Finally, we use the social cost of carbon, which reflects the cost of adding carbon emissions to the atmosphere, as an example of how analysis of climate impacts is sensitive to ethical assumptions. We consider $20 a reasonable lower bound for the social cost of carbon, but we show that a much higher value is warranted given a strong concern for equity within and across generations.

3.
Vaccine ; 39(2): 309-316, 2021 01 08.
Article in English | MEDLINE | ID: covidwho-974716

ABSTRACT

A vaccine for COVID-19 is urgently needed. Several vaccine trial designs may significantly accelerate vaccine testing and approval, but also increase risks to human subjects. Concerns about whether the public would see such designs as ethical represent an important roadblock to their implementation; accordingly, both the World Health Organization and numerous scholars have called for consulting the public regarding them. We answered these calls by conducting a cross-national survey (n = 5920) in Australia, Canada, Hong Kong, New Zealand, South Africa, Singapore, the United Kingdom, and the United States. The survey explained key differences between traditional vaccine trials and two accelerated designs: a challenge trial or a trial integrating a Phase II safety and immunogenicity trial into a larger Phase III efficacy trial. Respondents' answers to comprehension questions indicate that they largely understood the key differences and ethical trade-offs between the designs from our descriptions. We asked respondents whether they would prefer scientists to conduct traditional trials or one of these two accelerated designs. We found broad majorities prefer for scientists to conduct challenge trials (75%) and integrated trials (63%) over standard trials. Even as respondents acknowledged the risks, they perceived both accelerated trials as similarly ethical to standard trial designs. This high support is consistent across every geography and demographic subgroup we examined, including vulnerable populations. These findings may help assuage some of the concerns surrounding accelerated designs.


Subject(s)
COVID-19 Vaccines/administration & dosage , COVID-19/prevention & control , Decision Making , Pandemics/prevention & control , Research Design , SARS-CoV-2/immunology , Vaccination/psychology , Asia/epidemiology , Australia/epidemiology , COVID-19/epidemiology , COVID-19/psychology , COVID-19/virology , COVID-19 Vaccines/biosynthesis , COVID-19 Vaccines/supply & distribution , Choice Behavior , Clinical Trials as Topic , Female , Humans , Immunity, Innate/drug effects , Immunization Schedule , Immunogenicity, Vaccine , Male , North America/epidemiology , Patient Safety , Public Health , SARS-CoV-2/pathogenicity , Surveys and Questionnaires , Time Factors , United Kingdom/epidemiology , Vaccination/methods
SELECTION OF CITATIONS
SEARCH DETAIL